# Ogeda

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ogeda

- Industry: Pharmaceuticals
- Headquarters: Brussels, Belgium
- Website: www.euroscreen.com
- Total disclosed funding: $18M
- Latest round: Series B (Oct 27, 2015)
- Investors on record: 6

## About

Ogeda, based in Brussels, Belgium, specializes in developing innovative pharmaceutical solutions. The company focuses on advancing treatment options in various therapeutic areas, particularly in women's health.Ogeda, formerly Euroscreen SA, was founded in 1994 and is headquartered in Brussels, Belgium. The company primarily focuses on pharmaceutical development, with notable involvement in women's health treatments. In October 2016, Ogeda raised EUR 2 million in Series B funding as part of a larger EUR 18 million funding round. The company has executed a total of 5 deals, with the most recent deal finalized in 2016. Details regarding founders or changes in business operations are not publicly available.Ogeda primarily offers innovative pharmaceutical products targeting women's health. The company does not have a retail presence, instead focusing on research and development to create effective treatments tailored to specific health conditions in this demographic.Ogeda's revenue model is centered on its pharmaceutical products, with funding structured around the development and commercialization of these solutions. The company generated EUR 2 million from its latest funding round, reflecting its ongoing commitment to advancing its product pipeline in women's health.Ogeda aims to expand its product offerings in women's health, with plans to launch new treatments by 2025. The company intends to leverage its recent EUR 2 million Series B funding, raised in October 2016, to support research and development initiatives and expand into new markets, including North America and Asia by 2024. These efforts will enhance Ogeda's capabilities and market reach in the pharmaceutical landscape.

## Funding rounds

- Series B, Oct 27, 2015, $9.7M — Capricorn Partners, BNP Paribas Fortis, Société Régionale d'Investissement de Wallonie, Vesalius Biocapital, SFPI-FPIM, Fund+
- Series A, Dec 12, 2012, $8.7M — Société Régionale d'Investissement de Wallonie, Vesalius Biocapital

## Investors

- Société Régionale d'Investissement de Wallonie — Series A, Series B
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series A, Series B
- Capricorn Partners (https://capitalatlas.ai/funds/capricorn-partners) — Series B
- BNP Paribas Fortis — Series B
- SFPI-FPIM — Series B
- Fund+ (https://capitalatlas.ai/funds/fund) — Series B